Navigation Links
P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth
Date:10/29/2008

OTHER OPERATING ASSETS &

LIABILITIES 265 193

OTHER (68) 194

TOTAL OPERATING ACTIVITIES 3,251 3,230

INVESTING ACTIVITIES

CAPITAL EXPENDITURES (699) (540)

PROCEEDS FROM ASSET SALES 545 274

ACQUISITIONS, NET OF CASH

ACQUIRED (292) 12

CHANGE IN INVESTMENTS 34 (165)

TOTAL INVESTING ACTIVITIES (412) (419)

FINANCING ACTIVITIES

DIVIDENDS TO SHAREHOLDERS (1,254) (1,138)

CHANGE IN SHORT-TERM DEBT 3,629 1,295

ADDITIONS TO LONG TERM DEBT 878 2,012

REDUCTION OF LONG TERM DEBT (1,287) (3,692)

TREASURY PURCHASES (3,911) (2,598)

IMPACT OF STOCK OPTIONS AND OTHER 405 477

TOTAL FINANCING ACTIVITIES (1,540) (3,644)

EXCHANGE EFFECT ON CASH (110) 105

CHANGE IN CASH AND CASH EQUIVALENTS 1,189 (728)

ENDING CASH 4,502 4,626

Certain amounts for prior periods were reclassified to conform with the

fiscal 2009 presentation

THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES

(Amounts in Millions)

Consolidated Balance Sheet Information

September 30, June 30,

2008
'/>"/>

SOURCE The Procter & Gamble Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Cardinal Health Reports First Quarter Results
2. uKarma Reports Progress With International Distribution Agreement for Its Xflowsion DVD Series
3. STAAR Surgical Reports 33% Third Quarter Revenue Growth
4. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
5. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
6. LCA-Vision Reports Third Quarter 2008 Financial Results
7. Universal Health Services, Inc. Reports 2008 Third Quarter Results
8. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
9. Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009
10. WellPoint Reports Third Quarter 2008 Results
11. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...sion May Be Revealed Friday, January 9 , , WAS... Service Employees International Union (SEIU) Pres... SEIU International Executive Board to discuss the...re members out of SEIU United Healthcare Workers-W...d the final decision until tomorrow. , , Accord...
(Date:1/8/2009)...pts Prenatal Solution Key Factor in Decision for F...RLANDO, Fla., Jan. 8 All...LLC, one of the largest multi-specialty group prac... the Allscripts Enterprise(TM) Electronic Health R...cians in 18 offices across Central Florida. , ...
(Date:1/8/2009)...d., Jan. 8 Hanger Ortho...ounce that throughout the fourth quarter of 2008 i...nter, Rocky Mountain Orthotic-Prosthetics Center, ..., First Coast Orthotics & Prosthetics, and Ort...itions add patient care centers to existing market...
(Date:1/8/2009)... Jan. 8 The Pew Charita...been named director, chemical and food safety prog...ogram. Olson, who was formerly deputy staff direct...Environment and Public Works, brings nearly 25 yea...mer advocacy to Pew. , , "We are excited to be...
Breaking Medicine News(10 mins):Health News:SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers Delayed 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2
...n predict the mortality risk in patients hospitali...ndings // of a recent study. According to research...r the treatment of acute heart failure and offers ...ality risk upon hospital admission and quickly dec...
...arch has indeed unleashed several social and moral... and individuals to introspect within themselves./...n the understanding of human development. A recen...am from the University of Pittsburg, has opened pe...
...ondhand tobacco smoke could eventually lead to lun...// later in life say researchers based on findings...23,000 people who had either never smoked themselv... years participated in the study. Results showed p...
...rt disease risk factors may reduce the risk of dem...nt study // which shows that cardiovascular risk f...e risk of dementia in old age. Risk factors for c...sterol, hypertension, diabetes and smoking. Each o...
Other Medicine News:
(Date:1/7/2009)... INDIANAPOLIS, Jan. 7 El...y that it received a complete response letter from...olanzapine long-acting,injection (LAI) for acute ...lts. Lilly is continuing to work with the agency o...A does not require any additional clinical trials ...
(Date:1/7/2009)...JING, Jan. 7 Tiantan Puhua Hospita...m ), the worldwide leader in using stem cells to e... today six new globally experienced additions to i...xpand the hospital,s treatment capabilities for gr...The six senior doctors include the distinguished D...
(Date:1/6/2009)... YORK, Jan. 6 The Micha... million to four industry research teams for pre-c...arkinson,s disease. , , The funding was awarded...Initiative. This program, first launched in 2006,... Parkinson,s research. TDI is part of MJFF,s foc...
(Date:1/5/2009)... DIEGO, Jan. 5 Cylene Pharmaceutic...I clinical trial of its oral CK2 protein kinase in...tumors, Castleman,s disease, or multiple myeloma. ...trial are determination of safety, tolerance and P...ate dose for Phase II trials. In addition, multipl...
Breaking Medicine Technology:FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 2FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 3FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 4FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 5FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults 6Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3Labor 26 Medical Industry Give 56 25 of Prop 93 24 24 to Win Concessions in Health Care Legislation 8422 1Labor 26 Medical Industry Give 56 25 of Prop 93 24 24 to Win Concessions in Health Care Legislation 8422 2Labor 26 Medical Industry Give 56 25 of Prop 93 24 24 to Win Concessions in Health Care Legislation 8422 3TriWest Contributes 2415 000 to Kansas National Guard Fund 8420 1TriWest Contributes 2415 000 to Kansas National Guard Fund 8420 2Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 1Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 2Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 3Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 4Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 1Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 2Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 3Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 4Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 5
... Data presented at 12th Congress of European Hemat...e-FirstCall/ -- Alexion,Pharmaceuticals, Inc. toda...II studies examining Soliris(TM) (eculizumab) for ...ia (PNH) at the 12th,Congress of European Hematolo...on (EHA) in Vienna. These presentations,included: ...
...ARIS--(BUSINESS WIRE)--Jun 11, 2007 - Regulatory N...liminary data from the,ongoing phase III study for...relin do not support the expected sustainable bloo... in all patients.,Therefore, Ipsen has decided not...n the protocol. No safety concerns have,been obser...
Other Medicine Technology:Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 2Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 3Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 4Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 5Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 6Studies Show Efficacy and Safety of Alexion's Soliris in Broad,Population of PNH Patients 7Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration 2Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration 3
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique. Round knurled handle. Manufactured in titanium.
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches.
7 mm flattened hook. Flat serrated handle with polished finish. Overall length: 4.9 inches.
Left angled 5 mm blunt hook. Overall length: 9.9 inches.
Medicine Products: